The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

As a precautionary measure, Lupin Pharmaceuticals, Inc. is initiating a **recall** of lot **F305292, Expiry: August 2025** of **Cefdinir for Oral Suspension USP 125 mg/5 mL and** lot **F305442, Expiry: August 2025** of **Cefdinir for Oral Suspension USP 250 mg/5 mL to** the **retail** level. These lots are being recalled due to product complaint indicating foreign material being reported in the reconstituted bottle.

Although foreign material was not observed during reconstitution of product (at the dispensing pharmacy), out of an abundance of caution, a recall is initiated. The health hazard associated with the reported presence of foreign material could not be conclusively assessed. The recalled lots were distributed between October 2023 to April 2024 to wholesalers and distributors and drug chain stores nationwide.

Cefdinir for Oral Suspension USP 125 mg/5 mL and Cefdinir for Oral Suspension USP 250 mg/5 mL supplied as:

Strength	Lot	Expiry	NDC	Description
125 mg/ 5 mL	F305292	August-2025	68180-722-04	Off-white to creamish powder, free from lumps and agglomerates, forming off-white to creamish suspension with characteristic odour on constitution.
250 mg/ 5 mL	F305442	August-2025	68180-723-04	